BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at UBS Global Healthcare Conference Transcript

May 20, 2019 / 05:30PM GMT
Release Date Price: €9.58 (-0.04%)
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst

Okay. Great. Good afternoon. My name is Carter Gould. I'm senior biotech analyst here at UBS. Welcome to day 1 of our Global Healthcare Conference. I'm pleased to invite BioXcel Therapeutics to present next. Presenting for the company will be CEO, Vimal Mehta. The company had their first Phase I data today on their sublingual film. And they've got an important analyst day coming up later in the week. So important time here as they move forward with their lead asset. So Vimal?

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director

Thank you, Carter. Good afternoon. Thanks for joining us today. I'm excited to share BioXcel Therapeutics' story with you. We became a public company last March, in March of 2018. And today, we announced our first data for our 501 program which is a sublingual thin film. Before I begin, I'd like to remind you of the forward-looking statement as I will be making some statement which are forward looking, so I'd

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot